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Rhesus macaqueEpigenetic modiﬁcations mediated by histone deacetylases (HDACs) play important roles in the mechanisms
of different neurologic diseases and HDAC inhibitors (HDACIs) have shown promise in therapy. However,
pharmacodynamic proﬁles of many HDACIs in the brain remain largely unknown due to the lack of validated
methods for noninvasive imaging of HDAC expression-activity. In this study, dynamic PET/CT imaging was
performed in 4 rhesus macaques using [18F]FAHA, a novel HDAC substrate, and [18F]ﬂuoroacetate, the
major radio-metabolite of [18F]FAHA, and fused with corresponding MR images of the brain. Quantiﬁcation
of [18F]FAHA accumulation in the brain was performed using a customized dual-tracer pharmacokinetic
model. Immunohistochemical analyses of brain tissue revealed the heterogeneity of expression of individual
HDACs in different brain structures and cell types and conﬁrmed that PET/CT/MRI with [18F]FAHA reﬂects the
level of expression-activity of HDAC class IIa enzymes. Furthermore, PET/CT/MRI with [18F]FAHA enabled
non-invasive, quantitative assessment of pharmacodynamics of HDAC inhibitor SAHA in the brain.
© 2012 Elsevier Inc. Open access under CC BY license.Introduction
The status of histone acetylation in the brain, that is regulated by co-
operative functions of histone acetyl transferases (HATs) and histone
deacetylases (HDACs), has received much attention during the last de-
cade (Abel and Zukin, 2008; Jenuwein and Allis, 2001). Epigenetic
mechanisms involving modiﬁcations of histones has been implicated
in the development of various neurodegenerative diseases, multiple
sclerosis, and epilepsy (Janssen et al., 2010; Kazantsev and Thompson,
2008;Mai et al., 2009;Monti et al., 2009; Tsankova et al., 2007). Histone
deacetylase inhibitors (HDACIs) have shown efﬁcacy in therapy of neu-
rodegenerative diseases (Butler and Bates, 2006; Dietz and Casaccia,
2010; Sadri-Vakili and Cha, 2006). HDACIs increase the expression ofl Diagnostic Imaging, University
venue, room T8.3904, Houston,
ovani).
license.neuroprotective proteins, such as Hsp70 and Bcl-2 in the ischemic
brain, which points to the therapeutic potential of HDACIs in stroke
(Faraco et al., 2006). In models of motor neuron disease, such as the
amyotrophic lateral sclerosis, inhibition of HDACs resulted in a reduc-
tion of clinical symptoms (Ryu et al., 2005). HDACIs have also shown
promise in therapy of peripheral nerve damage (Cui et al., 2003). The
involvement of HDACs in the mechanisms of development of alcohol-
ism (Pandey et al., 2008) and drug addiction (Crepaldi and Riccio,
2009; Renthal and Nestler, 2009) and the effects of HDACIs in these
disorders have been demonstrated as well (Kalda et al., 2007;
Sanchis-Segura et al., 2009).
However, the pharmacodynamic (PD) proﬁles of several HDACIs in
the brain are largely unknown, which complicates the optimization
and individualization of treatment protocols. The PD effects on HDACIs
is often assessed in surrogate tissues (i.e., peripheral bloodmononuclear
cells Ronzoni et al., 2005) bymeasuring the levels of acetylated histones,
which does not necessarily correlate with therapeutic responses in the
brain and other tissues (Chavez-Blanco et al., 2005; Kelly et al., 2005).
Also, it is not known whether there is a requirement for continuous
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are no predictive biomarkers for selection of patientswho aremost likely
to respond to treatment with HDACIs (Kelly et al., 2005; Minucci and
Pelicci, 2006). The assessment of pharmacodynamics of HDACIs in CNS
is complicated due to an unacceptable traumatism of microdialysis and
biopsy procedures. Therefore, novelmolecular imaging agents for visual-
ization and quantiﬁcation of HDAC activity in the brain are urgently
needed to facilitate the development and clinical translation of novel
HDACIs.
To address this need, we have been developing agents and methods
for molecular imaging of pharmacodynamic effects of HDACIs using
magnetic resonance spectroscopy (MRS) (Sankaranarayanapillai et al.,
2006). Also, we developed a novel radiolabeled HDAC substrate, the
6-([18F]ﬂuoroacetamido)-1-hexanoicanilide, termed [18F]FAHA,
for non-invasive PET imaging of HDAC activity in the brain
(Mukhopadhyay et al., 2006). Our initial in vitro and in vivo PET
imaging studies in rats demonstrated a signiﬁcant accumulation of
[18F]FAHA in the brain already at 30 min after the radiotracer adminis-
tration (Nishii et al., 2007). Subsequently, [18F]FAHA PET with simpliﬁed
pharmacokinetic (PK) modeling was used to assess SAHA-induced inhi-
bition of HDAC activity in the brain of non-human primates (Reid et al.,
2009).
In the current study, we performed PET/CT/MRI imaging with [18F]
FAHA in rhesus macaques and quantiﬁed the rate of HDAC-mediated
accumulation of [18F]FAHA in the brain using a new optimized phar-
macokinetic model. To account for contribution of [18F]ﬂuoroacetate
([18F]FACE), the major catabolite of [18F]FAHA, to the levels of [18F]
FAHA-derived radioactivity measured in the brain, an additional PET/CT
study with [18F]FACE was conducted in each animal. The results of in
vivo PET/CTMRI studies were validated using radiochemical and immu-
nohistochemical analyses of brain tissue, revealing the heterogeneity of
expression of individual HDACs in different brain structures and cell
types. This study demonstrated that PET/CT/MRI with [18F]FAHA reﬂects
the level of expression-activity of HDAC class IIa enzymes in different
structures of the brain and enables non-invasive, quantitative assess-
ment of pharmacodynamics of HDAC inhibitor SAHA (vorinostat).
Methods
Radiosynthesis of [18F]FACE and [18F]FAHA
The radiosynthesis of [18F]FACE was performed as described by us
previously (Nishii et al., 2012). Speciﬁc activity of [18F]FACE was
1.162 Ci/μmol (43 GBq/μmol). The radiosynthesis of [18F]FAHA was
performed as described by us previously (Mukhopadhyay et al., 2006).
Decay-corrected yield was 11±2% and speciﬁc activity >2 GBq/mmol.
Assessment of substrate speciﬁcity of FAHA for different HDACs
In vitro enzyme assays were performed in a panel of classes I, II, III,
and IV HDACs (BPS Bioscience, San Diego, CA) in the buffer: 25 mM
Tris/Cl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, and 0.1 mg/ml
BSA, 10 ng of each HDAC enzyme and different concentrations of
non-radilabeled FAHA. Reactions were carried out for 30 min at 30 °C
and products determined by HPLC using Ascentis RP-amide 7×300 mm
column (Supelco), MeCN/0.02 mM O-phosphoric acid as mobile phase
at 0.6 ml/min with UV detection of the cleaved product (hexanoic
anilide) at 240 nm. The Km, Vmax and Kcat parameters were determined
using software GraphPad Prism v4 (GraphPad Software, La Jolla, CA).
Management of non-human primates
All studies were performed under a protocol approved by the In-
stitutional Animal Care and Use Committee of the University of
Texas M.D. Anderson Cancer Center (UTMDACC). Four rhesus macaques
(2males and 2 females) under anesthesia were studied. Prior to imagingstudies, the animalswere fasted overnight, but had a free access towater.
The animals were premedicated with atropine sulfate 0.04 mg/kg in-
tramuscularly (i.m.) and sedated with ketamine 10–15 mg/kg i.m.,
followed by intubation and inhalation anesthesia with isoﬂurane 1–3%
in oxygen via Excel 210 SE (Ohmeda). Then, the animalswere cannulated
in both saphenous veins: one, for injection of 18F-FAHA or 18F-FACE; the
other, for blood sampling. Body temperature was maintained at 37 °C
with warming blanket (Model 505; Arizant Healthcare). Electrocardio-
gram, respiration, blood pressure and oxygenation were monitored
with Solar 8000 (Marquette Medical Systems, WI).
MRI/PET/CT imaging studies
MR imaging was performed on an 8-channel 1.5 T HDx scanner with
CRMgradient subsystem (GEHealthcare,WI). T1-weighted imageswere
acquired using an inversion recovery-prepared 3D fast spoiled gradient
recalled echo (FSPGR) sequence (12 degree ﬂip angle, TE/TR=4.9/
10.4 ms, 18×18 cm FOV, 320×320 acquisition matrix,1.2-mm sections
reconstructed every 0.6 mm, ±21 kHz bandwidth). T2-weighted im-
ages were acquired using a 3D T2 CUBE imaging sequence (TE/TR=
128/3000 ms, echo train length: 120, 18×18 cm FOV, 320×320 acquisi-
tion matrix, 1.2-mm sections reconstructed every 0.6 mm, ±31 kHz
bandwidth). The T1- and T2-weighted images were reformatted into
1-mm thick contiguous images in three orthogonal planes.
PET/CT imaging was performed using Discovery STE16 (GE
Healthcare, WI); the axial ﬁelds-of-view (FOV) of CT and PET were
50 cm and 70 cm, respectively. Transmission CT images of the head
was used to verify the accuracy of positioning tomatch the prior MR im-
ages. The ﬁrst PET imaging study was performed with 18F-FACE (5.95±
0.96 mCi in 5 ml saline) administered as a steady bolus over 1 min, as
described before (Nishii et al., 2012; Tian et al., 2011). Dynamic PET im-
ages were acquired over 30 min. The second PET imaging study with
[18F]FAHA (6.07±0.75 mCi/5 ml) was performed one week later using
a similar protocol. Venous blood samples (0.5 ml) were obtained at: 0,
1, 2, 3, 5, 10 and 30 min for the analysis of radiolabeled metabolites
([18F]FACE and [18F]ﬂuoride). PET images were reconstructed from the
list-mode data for the following time frames: 12×15 s, 6×30 s, and
25×60 s; (total of 33 frames/study) using an iterative algorithm
VuePoint (GE Healthcare) with 2 iterations, 28 subsets, 20 cm DFOV,
kernel width 2.0 mm FWHM and a standard z-axial ﬁlter, with scatter
and attenuation corrections. PET images had a resolution of 128×128
voxels with spatial resolution of 4.4 mm full width at half maximum
(FWHM) and slice thickness of 3.25 mm.
MR images were coregistered to the corresponding PET/CT images
summed from dynamic 30 min scans using a rigid transformation al-
gorithm and a normalized mutual method after running a re-slicing
process with software PMOD version 3.1 (PMOD Technologies, Zurich,
Switzerland). Volumes-of-interest (VOI) for carotid artery, whole brain,
n. accumbens and cerebellum were deﬁned and time activity curves
(TACs) generated.
Assessment of radiolabeled metabolites in blood plasma
The radioactivity concentration in the whole blood and plasma was
assayed using a gamma counter (Cobra, Packard, CT). Plasma was
extracted from heparinized blood samples (0.5 ml) with 3× volumes of
acetonitrile and analyzed with radio-HPLC: 1100 HPLC (Agilent, Santa
Clara, CA), UV and radioactivity detectors (Bioscan Inc., Washington,
DC); Supelcogel C-610H column (Sigma-Aldrich, MO); mobile phase:
35% MeCN/Phosphoric acid in water at 0.6 ml/min. This method affords
separation of [18F]FAHA (elution at 18.1–18.4 min) and [18F]FACE
(elution at 11.1–11.5 min). Fractions of [18F]FAHA and [18F]FACE
were calculated for each sample based on the area under each peak.
The total radioactivity in plasma was expressed as %ID/ml and plotted
against time post injection of [18F]FAHA. The %ID/ml of [18F]FAHA and
[18F]FACE were calculated based on the results of radio-HPLC analysis
Fig. 1. Graphical representation of a novel multi-compartmental pharmacokinetic
model with two simultaneous blood input functions for [18F]FAHA and [18F]FACE
(see explanation in the Methods section).
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concentration ratio was calculated from blood samples obtained at dif-
ferent times post 18F-FAHA administration and used for quantiﬁcation
of PET images, as described further.
Assessment of [18F]FAHA-derived radiolabeled metabolites in the brain
This study was performed under the approval of the RIKEN Kobe
Institute Animal Committee (MAH21-13), Kobe, Japan. One rhesus
macaque was anesthetized with ketamine (10 mg/kg) and atropine
(0.08 mg/kg) for placement of an i.v. catheter. Then, the animal was
placed into the specialized primate chair, and after recovery from an-
esthesia, [18F]FAHA (37 MBq/kg) was administered as a quick bolus
injection. Three minutes later, the animal was deeply anesthetized
by a bolus of pentobarbital (30 mg/kg, i.v.) and heparinized (1000U
i.v.). At 7 min post injection of [18F]FAHA, the intracardiac perfusion
with ice-cold 10 mM PBS was performed through the left ventricle
and the animal sacriﬁced. The whole brain was quickly removed
(within 10 min), sliced into 6 mm thick sections, and frozen in liquid
nitrogen; different structures of the brain were dissected, weighed,
and homogenized using an equal amount of ice-cold ddH2O. Brain tis-
sue homogenates were mixed with 3 volumes of acetonitrile for 30 s
and centrifuged at 10,000×g for 2 min at 4 °C. The supernatants were
spotted (2 μl/spot) on a TLC plate silica 60 (Merck, Germany), devel-
oped using acetonitrile/water/ammonia hydroxide (90/9/1), and quan-
tiﬁed by the imaging plate analyzer FLA-7000IR (Fujiﬁlm, Japan).
PET image analyses and pharmacokinetic modeling
First, to calculate dynamic PET image-derived input functions for
[18F]FAHA and [18F]FACE in blood plasma, the TAC was measured
from the region of interest placed on the carotid artery and corrected
using the mean plasma-to-whole blood radioactivity concentration
ratio measured in blood samples (as described above). Then, fraction-
al values of radioactivity concentrations of [18F]FAHA and [18F]FACE
measured in venous blood plasma samples at different times post
[18F]FAHA administration were applied to the image-derived plasma
TAC to derive the corresponding TACs for [18F]FAHA and [18F]FACE,
respectively.
The newly developed pharmacokinetic model of [18F]FAHA-derived
radioactivity accumulation in the brain, involves two blood plasma
input functions for [18F]FAHA and [18F]FACE and three tissue com-
partments described in Fig. 1. In this model, we considered that
[18F]FAHA can cross the blood–brain barrier (BBB) and cell mem-
branes bi-directionally by non-facilitated diffusion, which is due to
its physicochemical characteristics (LogD 1.44; PSA 58.2; FRD 8;
LogBB −0.51). Therefore, the rate constants of [18F]FAHA inﬂux
(k1FAHA) and efﬂux (k2FAHA) across the BBB and cell membranes were
assumed to be high and not rate-limiting. Upon entry into the cell,
[18F]FAHA is metabolized by HDACs to [18F]FACE and nonradiolabeled
hexanoic anilyde,which is described by the rate constant k3FAHA. Because
there are no known enzymes that would effectively catalyze the
back-reaction to produce [18F]FAHA from [18F]FACE and hexanoic
anilyde, the rate constant k4FAHA describing this reaction was set to zero.
Also, we considered that a fraction of [18F]FACE produced inside the
brain cells from [18F]FAHA can be trapped inside the cells due to high po-
larity and low lipophilicity of [18F]FACE, which limit its efﬂux (k2FACE)
out of the cells. Furthermore, [18F]FACE can be progressively anabolized
to [18F]ﬂuoroacetyl-coA by acetyl-coA synthases ACS1 and ACS2, and
by the citrate synthase to [18F]ﬂuorocitrate, which binds irreversibly to
aconitase (Fonnum et al., 1997; Proudfoot et al., 2006). However,
there is no effective catabolism of ﬂuoroacetyl-coA, ﬂuorooxalate, and
ﬂuorocitrate back to ﬂuoroacetate, which accounts for its neurotoxicity
at pharmacologically relevant doses (Fonnum et al., 1997; Proudfoot et
al., 2006). Therefore, the rate constant k4FACE was set to zero.Furthermore, we considered that [18F]FACE produced from catab-
olism of [18F]FAHA in organs and tissues other than brain, appears in
plasma as the major radiolabeled metabolite and can contribute to ra-
dioactivity accumulation in the brain. It is known that [18F]FACE can
cross BBB via the monocarboxylate transporter (MCT) and be selec-
tively uptaken by the glial cells expressing MCT (Fonnum et al.,
1997; Proudfoot et al., 2006). Therefore, the rate constants for inﬂux
(k1FACE) and efﬂux (k2FACE) of [18F]FACE across the BBB and cellular
membranes were considered to be relatively smaller than those of
[18F]FAHA.
Importantly, we considered the rates of [18F]FACE efﬂux (k2FACE)
and entrapment through anabolism to [18F]ﬂuorocitrate (k3FACE) in-
side the cells to be independent of the origin of the [18F]FACE (wheth-
er it is produced from [18F]FAHA inside the cell or is transported into
the cell from the outside, as the major metabolite of [18F]FAHA in
blood).
This approach requires a separate dynamic PET imaging study
with [18F]FACE to calculate the rate constants k1FACE, k2FACE, and
k3FACE for the brain. To achieve this, brain TACs of [18F]FACE-derived
radioactivity were ﬁtted to the irreversible two-tissue compartment
model (Fig. 1) with a variable blood volume to estimate the rate con-
stants k1FACE, k2FACE, k3FACE, using the dynamic imaging-derived [18F]
FACE input function corrected by blood plasma sampling results, as
described above in detail. Because there is no catabolism of ﬂuorocitrate
back into ﬂuoroacetate, the k4FACEwas set to zero and the unidirectional
accumulation rate constant of [18F]FACE (KiFACE) was calculated as:
KiFACE ¼ k1FACE⋅k3FACE= k2FACE þ k3FACEð Þ: ð1Þ
Subsequently, the rate constants k1FACE, k2FACE, and k3FACE obtained
from the PET imaging study with [18F]FACE alone were used as ﬁxed
rate constants in themodel of [18F]FAHA-derived radioactivity accumu-
lation in the brain (Fig. 1). The unidirectional accumulation rate con-
stant of [18F]FAHA (KiFACE) was calculated as:
KiFAHA ¼ k1FAHA⋅k3FAHA= k2FAHA þ k2FACEð Þ: ð2Þ
Compartmental modeling, pharmacokinetic analyses, and genera-
tion of pixel-by-pixel parametric images were accomplished using
PMOD 3.1 software (PMOD Technologies Ltd., Zurich, Switzerland).
Statistical analyses of data were performed using GraphPad Prism 4
(GraphPad software, La Jolla, CA, USA).
Fig. 2. Enzymatic activity of different HDACs with FAHA. (A) Kcat data for different HDACs are shown in full scale and (B) the same data as in panel A are shown on a smaller scale to
better visualize differences in Kcat data for HDACs classes I, II, III, and IV.
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accumulation in the brain
Four rhesus macaques (2 males and 2 females) were used to obtain
the dose–response proﬁles of the impact of [18F]FAHA accumulation in
the brain by vorinostat (SAHA). PET imaging studies were performed in
each rhesus macaque: (a) baseline study with [18F]FACE; (b) baseline
study with [18F]FAHA; and (c) 7 separate studies with [18F]FAHA after
treatment with different doses of SAHA (0.001, 0.01, 0.1, 1, 10, 50,
100 mg/kg i.v.), which was administered as a continuous infusion
over 1 h prior to [18F]FAHA administration. The time-course of radioac-
tivity of [18F]FAHA in the brain after administration of escalating doses
of selected HDAC inhibitor was assessed and compared to the baseline.
Immunohistochemical staining of class I and II HDACs and acetyl-histones
in the brain
Formalin-ﬁxed, parafﬁn-embedded brain samples were cut (5 μm),
deparafﬁnized, rehydrated, and microwaved in 10 mM citrate buffer
(pH 6.0) at 95 °C for 10 min; then incubated in 3% H2O2 for 15 min
and blockedwith 1.5% rabbit or goat serum in PBS for 60 min. Then, sec-
tions were incubated overnight at 4 °C with primary antibodies diluted
1:50 in 1% TBS: HDACs 1, 2, 3, 5, 7, 8, and 9 (Santa Cruz Biotech., CA);Fig. 3. Pharmacokinetics of [18F]FACE after i.v. administration. (A) Time-course of [18F]FACE (p
and (B) as fraction of total radioactivity. (C) Comparison of [18F]FACE-derived time-activity cuHDACs 4 and 6 (Cell Signaling Technology, MA), HDACs 10–11
(Sigma-Aldrich, MO); and AH2A-K5, AH2B-K5, AH2B-K20, AH3-K9,
AH3-K18, AH3-K23, AH4-K8, and AH4-K12 (Cell Signaling, MA).
Biotinylated secondary antibodies and 3,3-diaminobenzidine from the
Vectastain Elite kit (Vector Laboratories, CA) were used according to
themanufacturer's protocol. The sectionswere counterstainedwith he-
matoxylin and evaluated onBX51microscope, equippedwithDP71dig-
ital camera (Olympus, Japan).
Results
Substrate speciﬁcity of FAHA to class IIa HDAC enzymes
In vitro enzymatic studies demonstrated that FAHA has higher
substrate speciﬁcity for class IIa HDACs with Kcat values two orders
of magnitude higher than for other classes of HDACs (Fig. 2).
The time course of [18F]FACE and radiolabeled metabolites in blood and
brain
After intravenous administration of [18F]FACE, the clearance of ra-
dioactivity from plasma followed a bi-exponential kinetics with the
fast phase between 3 and 18 min with a half-life of 4 min, followedarent) and [18F]ﬂuoride (metabolite) radioactivity in blood plasma, expressed as %ID/ml,
rves in n. accumbens, cerebellum, and blood. Data — average±st.dev.
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[18F]FACE administration, only negligible traces of [18F]ﬂuoride were
detectable in the blood plasma (b2% of total radioactivity) (Fig. 3B). Par-
tition of [18F]FACE-derived radioactivity in blood between RBCs and
plasma was 70.2±8.4%. Dynamic PET/CT/MRI imaging demonstrated
very low, uniform distribution of [18F]FACE-derived radioactivity
(Fig. 4A). The levels of [18F]FACE-derived radioactivity concentration
between 0 and 30 min post injection were lower than that in blood
plasma (Fig. 3C). The whole brain-to-blood and brain-to-muscle
concentration ratios of [18F]FACE at 30 min post injection remained
low, 0.55±0.18 and 0.78±0.28, respectively. Parametric images of
[18F]FACE accumulation in the brain (Fig. 4B) also demonstrated
very low Ki values in the forebrain and cerebellum, 0.006±0.003 and
0.003±0.003 min−1, respectively. The rate constants k1, k2, k3 and Ki
of [18F]FACE in different structures of the brain are provided in Table 1.Fig. 4. Axial PET/MRI fusion images of the brain obtained after i.v. administration of [18F]FACE
30 min post administration of [18F]FACE (A) or [18F]FAHA (C) color-coded to the range of %ID
Ki of [18F]FACE (B) or [18F]FAHA at baseline (D) and after escalating doses of SAHA (E–J) obThe time course of [18F]FAHA and radiolabeled metabolites in blood and
brain tissue
After intravenous administration of [18F]FAHA, the clearance of total
radioactivity from plasma followed a bi-exponential kinetics with the
fast phase during the ﬁrst 3 min with a half-life of 30 s followed by a
slow phase with half-life of about 8 min (Fig. 5A). Systemic catabolism
of [18F]FAHA to [18F]FACE was fast, which contributed to a rapid
mono-exponential clearance of [18F]FAHA from the blood plasma with
the fast phase during the ﬁrst 2.5 min with half-life of 25 s followed by
a slow phasewith half-life of about 5.5 min. By 30 min post injection, al-
most all [18F]FAHA was catabolized to [18F]FACE (SI Appendix, Fig. S1).
PET/CT/MRI imaging demonstrated a rapid accumulation of [18F]
FAHA-derived radioactivity in the n. accumbens, amygdala, putamen,
subthalamic nuclei, periaqueductal gray, inferior collicules, cerebellum,or [18F]FAHA obtained at different axial levels. Static PET/MRI images were obtained at
/g values. Parametric PET/MRI images of the unidirectional accumulation rate constant
tained in the same animal and color-coded to the same range of Ki values (min−1).
Fig. 5. Pharmacokinetics of [18F]FAHA after i.v. administration. Time-course of parent [18F]FAHA radioactivity at baseline and after pretreatment of animals with increasing doses of
SAHA (color-coded in mg/kg) in (A) blood plasma, (B) n. accumbens, and (C) cerebellum. Data — average±st.dev.
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tional rate (Ki) of [18F]FAHA-derived radioactivity accumulation in the
brain, generated using the newly developed compartmental model, en-
hanced these observations (Fig. 4D). The whole brain Ki of [18F]FAHA
(0.145±0.123 min−1) was about 50-fold higher than Ki of [18F]FACE
(0.003±0.002 min−1). Higher levels of [18F]FAHA-derived radioactivi-
ty accumulation in different nuclei of the brain and in the cerebellum
were due to higher k3 rate constant values, reﬂecting higher activity
of HDAC class IIa enzymes. The inﬂux (k1) and efﬂux (k2) rate constants
of [18F]FAHA in different structures of the brain were 10 to 20 fold
higher than those of [18F]FACE, which is consistent with higher lipophi-
licity of [18F]FAHA. The rate constants k1, k2, k3, and Ki of [18F]FAHA for
different structures of the brain are summarized in Table 1.Radiolabeled metabolites in the brain
Analyses of radiolabeled metabolites in brain tissue extracts
obtained at 8–10 min post [18F]FAHA administration revealed [18F]Fig. 6. Dose dependent inhibition of the [18F]FAHA accumulation in different structures of t
shown for representative structures of the brain. Data — average±st.err.ﬂuorocitrate as the major radiolabeled metabolite entrapped in the
brain tissue (SI Appendix, Fig. S2).Dose-dependent changes in [18F]FAHA pharmacokinetics, metabolism,
and accumulation in different structures of the brain
Pretreatment of animals with increasing doses of SAHA resulted
in a dose-dependent log-linear increase in circulation half-time and
AUC of [18F]FAHA and corresponding decrease in AUC of [18F]FACE
radiometabolite (SI Appendix, Fig. S1). In contrast, a dose-dependent
inhibition of accumulation and the rate constant (Ki) of [18F]FAHA
were observed in different structures of the brain with increasing
doses of SAHA (Fig. 4E–J). The observed dose-dependent inhibition of
[18F]FAHA accumulation was due to reduction of the rate constant k3
for conversion of [18F]FAHA into [18F]FACE (Table 1). The IC50 values
of SAHA were calculated using Ki [18F]FAHA values for different struc-
tures of the brain (Fig. 6; Table 2). Higher IC50 values for SAHAwere ob-
served in periaqueductal gray, cerebellum, n. accumbens, inferiorhe brain. SAHA dose–response curves based on [18F]FAHA rate constants k3 and Ki are
Table 1
The rate constants inﬂuencing the accumulation of [18F]FACE and [18F]FAHA in different structures of the brain.
Brain regions FACE baseline FAHA baseline
k1 k2 k3 Ki k1 k2 k3 Ki
Whole brain 0.045±0.034 0.170±0.145 0.033±0.065 0.003±0.002 0.424±0.2637 0.611±0.5713 0.192±0.222 0.145±0.123
Putamen 0.024±0.033 0.059±0.063 0.026±0.031 0.008±0.003 0.708±0.3726 0.731±0.617 0.328±0.079 0.295±0.367
Thalamus 0.020±0.482 0.048±0.067 0.022±0.022 0.008±0.003 0.765±0.4308 0.604±0.365 0.192±0.032 0.223±0.165
Nucleus accumbens 0.056±0.052 0.179±0.146 0.025±0.034 0.004±0.003 0.626±0.5812 1.181±1.6532 0.401±0.296 0.663±0.913
Temporal cortex 0.016±0.046 0.037±0.014 0.033±0.018 0.008±0.004 0.438±0.2453 0.558±0.2452 0.158±0.056 0.116±0.191
Amygdala 0.020±0.035 0.088±0.063 0.047±0.040 0.006±0.004 0.512±0.1283 0.493±0.118 0.259±0.093 0.242±0.158
Peri-aqueductal gray 0.021±0.044 0.050±0.034 0.026±0.023 0.007±0.003 0.619±0.2961 0.554±0.256 0.236±0.088 0.260±0.080
Inferior colliculus 0.019±0.045 0.034±0.024 0.022±0.021 0.008±0.004 0.706±0.2366 0.644±0.312 0.267±0.108 0.301±0.234
Hippocampus 0.021±0.034 0.118±0.031 0.054±0.039 0.006±0.003 0.595±0.071 0.883±0.738 0.279±0.213 0.240±0.155
Cerebellum 0.055±0.054 0.202±0.125 0.044±0.066 0.003±0.003 0.645±0.2594 1.001±0.475 0.380±0.279 0.272±0.024
White matter 0.015±0.019 0.089±0.103 0.029±0.022 0.004±0.002 0.463±0.2052 0.810±0.269 0.187±0.135 0.111±0.012
636 H.-H. Yeh et al. / NeuroImage 64 (2013) 630–639colliculus, putamen, and amygdala. Relatively lower SAHA IC50 values
were observed in the hippocampus, temporal cortex, and whitematter.Expression of class I and II HDACs and acetylation status of histones in
different brain structures
In the n. accumbens (SI Appendix, Fig. S3), HDACs class I and class
IIa, were highly expressed, predominantly in the neurons, except for
HDAC 7, which was expressed in microvessels. In particular, high
levels of HDACs 4 and 5 expression were observed in neurons.
HDAC 6 was expressed in neurons and glia, whereas HDAC 10 was
expressed predominantly in glial cells. HDAC 11 was highly expressed
both, in neurons and glia (Fig. S4). H3-K18 was most deacetylated,
while H2B-K20 and H4K-12 were most acetylated.
In the hippocampus (SI Appendix, Figs. S5–9), HDACs 2, 3, and 10
were expressed at high levels, especially in the dentate gyrus (DG) neu-
rons. HDAC 5 was moderately expressed in CA2 and CA3 neurons,
whereas HDACs 1 and 4 were expressed the least (SI Appendix, Figs.
S6, S7). HDAC 6wasmoderately expressed in CA1 and DG (SI Appendix,
Figs. S5, S9). Moderate-to-high levels of HDAC 11 were observed
throughout hippocampus (SI Appendix, Fig. S5). H3-K18 was the most
acetylated, while H3-K9 and H3-K23 were the most deacetylated
throughout the hippocampus (SI Appendix, Fig. S11–14).
In the brain cortex (SI Appendix, Fig. S15), the level of expression of
class IIa HDACs was notably lower than that of the class I HDACs, and
lower than the expression of HDAC class IIa in the n. accumbens. HDAC
6 was expressed in the neurons and glia, whereas HDAC 10 was
expressed predominantly in the glia. HDAC 11 was expressed both, in
neurons and glia. H3-K18 was the most acetylated, while H3-K9 and
H3-K23 were the most deacetylated (SI Appendix, Fig. S16).
In the cerebellum (SI Appendix, Fig. S17), amongst class I HDACs,
high levels of HDACs 1 and 2 were observed in Bergmann microglial
cells, whereas high levels of 8 expression were observed in most of
the cell types. Amongst HDAC class IIa, high levels of HDACs 4 and 9Table 2
IC50 values of SAHA calculated using Ki [18F]FAHA values for different structures of the
brain.
Brain Structure IC50 Std.Err.
Whole brain 6.94 0.53
Putamen 3.34 0.46
Thalamus 1.81 0.51
N. accumbens 4.47 0.60
Temporal cortex 1.16 0.52
Amygdala 3.21 0.39
Peri-aquedutal gray 8.28 0.37
Inferior colliculus 4.42 0.36
Hippocampus 0.10 0.93
Cerebellum 6.10 0.45
White matter 0.32 0.77expressionwas observed in Purkinje cells, whereas HDAC 5wasmoder-
ately expressed in granular and molecular layer cells. HDAC 7 was
expressed in microvascular endothelial cells and as granules localized
in the pinceau terminals of basket neurons, embracing the Purkinje
cell bodies. Amongst HDACs class IIb, HDAC 6 was expressed predomi-
nantly in the Purkinje cells, whereas HDAC 10was expressed in granular
and molecular layer cells. HDAC 11 (class IV) was moderately expressed
in Brenner microglial cells. The acetylation of H2A-K5, H2B-K20, H3-K9,
H3-K18, H3-K23, andH4-K12,was almost non-detectable in the vastma-
jority of Purkinge cells. Low acetylation levels of H3-K23 were observed
in all cells in the cerebellum, whereas the lowest levels of H3-K9 acetyla-
tionwas observed in the granular layer cells. Highest levels of acetylation
of other histone lysine residues were observed in cells of the molecular
layer (SI Appendix, Fig. S18).
The results of qualitative assessment of expression of individual
HDAC isoforms in different brain structures are summarized in SI Ap-
pendix, Table S1. The acetylation status of certain lysine residues on
different histones is summarized in SI Appendix, Table S2.Discussion
There is increasing evidence thatHDAC-mediated epigenetic regula-
tion is involved in neurogenesis, neuronal plasticity, learning, memory
formation and recall, as well as CNS disorders including cognitive dys-
function, depression, addiction, and schizophrenia and several neuro-
degenerative diseases (for review: Fischer et al., 2010; Jiang et al.,
2008; Renthal and Nestler, 2009; Tsankova et al., 2007). Development
of novel isotype-selective HDAC inhibitors and the assessment of their
efﬁcacy for therapy of different brain diseases (Thomas, 2009) could
be facilitated by PET imaging with HDAC class and isotype-selective
agents.
In this study, we determined that [18F]FAHA exhibits preferential
substrate afﬁnity to class IIa enzymes (HDACs 4, 5, 7, and 9), which
is consistent with other reports demonstrating that triﬂuoro substitu-
tions in the methyl group of acetyl moiety of acetyl-lysine, increase
substrate speciﬁcity for the class IIa HDACs (Jones et al., 2008; Lahm
et al., 2007).
To quantify PET/CT/MR images of [18F]FAHA accumulation in the
brain we developed a new pharmacokinetic compartmental model
that is substantially different than previously reported simple one-
and two-compartmental models (Reid et al., 2009). We demonstrated
that due to high lipophilicity, [18F]FAHA crosses the cell membranes
and BBB by non-facilitated diffusion, as evidenced by high inﬂux and ef-
ﬂux rate constants k1FAHA and k2FAHA, respectively. In contrast, the in-
ﬂux and efﬂux rate constants of [18F]FACE are 10 to 20 fold smaller,
because ﬂuoroacetate is a hydrophilic molecule and does not cross
membranes easily and its transport across the blood–brain-barrier
and across glial and neuronal cell membranes is rate-limited by H+
coupled monocarboxylate transporters (MCTs). The MCT1 is expressed
predominantly by the brain microvascular endothelial and glial cells,
637H.-H. Yeh et al. / NeuroImage 64 (2013) 630–639whereas theMCT2 is expressed predominantly in neurons, especially in
the cortex, hippocampus, and cerebellum (Pierre and Pellerin, 2005).
Although after intravenous administration [18F]FAHA is gradually ca-
tabolized to [18F]FACE, the contribution of [18F]FACE circulating in the
blood to radioactivity accumulation in the brain, especially during the
ﬁrst 30 min post injection, is very small, as evidenced by an almost
50-fold lower KiFACE, as compared to KiFAHA. Nevertheless, the contribu-
tion of [18F]FACE as the major metabolite of [18F]FAHA circulating in
blood to accumulation of [18F]FAHA-derived radioactivity in the brain
was accounted for in the new pharmacokinetic model.
Inside the cells, [18F]FAHA is cleaved predominantly by the class IIa
HDAC enzymes releasing [18F]FACE, which efﬂuxes signiﬁcantly slower
than [18F]FAHA and causes retention of radioactivity in the brain. In the
current study, by analyzing radiolabeled metabolites in the brain ex-
tractswe demonstrated that [18F]FACE produced from [18F]FAHAby en-
zymatic activity of HDACs is further anabolized to [18F]ﬂuorocitrate.
Fluorocitrate is known to irreversibly bind to aconitase (Carrell et al.,
1970; Lauble et al., 1996) and is trapped inside the cells. The metabolic
retention of [18F]ﬂuorocitrate inside the cells is also evidenced by re-
sults of our previous studies on pharmacokinetics, metabolism, and ra-
diation dosimetry of [18F]FACE, in which the [18F]ﬂuorocitrate anabolite
was not detectable in blood up to 3 h post radiotracer administration
(Nishii et al., 2012). However, the rate of irreversible entrapment of
[18F]FACE due to anabolism into [18F]ﬂuorocitrate in the brain is slow,
as evidenced by a relatively low k3FACE, when [18F]FACE was adminis-
tered prior to [18F]FAHA imaging studies. This is consistent with the
known biochemistry and toxicology of FACE; ﬂuorocitrate formation
from FACE in the brain is a relatively slow process, which results in a de-
layed neurotoxicity (Clarke, 1991; Goncharov et al., 2006; Peters and
Wakelin, 1953). There are no known enzymes in the brain that would
directly de-ﬂuorinate [18F]FAHA or [18F]FACE, and which would cata-
lyze reverse reactions from [18F]ﬂuorocitrate back to [18F]FACE or
[18F]FACE back to [18F]FAHA. Therefore, in the compartmental model
used in this study, the rate constants k4FAHA and k4FACE were set to
zero. An important observation made in this study was that the rate of
HDAC-mediated cleavage of [18F]FAHA to [18F]FACE in the brain, de-
ﬁned as k3FAHA, was signiﬁcantly faster than the rate of anabolism and
irreversible entrapment of [18F]FACE deﬁned as k3FACE. On the other
hand, the efﬂux of [18F]FACE from the cells characterized by the rate
constant k2FACE was 4 to 10 fold less than that of [18F]FAHA. Therefore,
the accumulation of [18F]FAHA-derived radioactivity in different struc-
tures of the brain within the ﬁrst 30 min post i.v. injection is rate-
limited predominantly by the level of expression and activity of HDAC
class IIa enzymes in corresponding structures. However, the observed
pattern and magnitude of accumulation of [18F]FAHA-derived radioac-
tivity in different structures of the brain reﬂect the activity of class IIa
HDACs under general anesthesia, which may be different from that
under non-anesthetized conditions.
We decided to develop a radiolabeled substrate as opposed to
radiolabeled inhibitor of HDACs, because binding of a radiolabeled in-
hibitor to its target enzyme reﬂects only the magnitude of enzyme
expression/occupancy, but not necessarily the enzyme activity. Other
investigators have explored the feasibility of PET imaging of HDAC ex-
pression using radiolabeledHDAC inhibitors, such as [18F]suberoylanilide
hydroxamic acid, [18F]SAHA (Hendricks, et al., 2011; Zeglis, et al., 2011)
and [11C]MS-275 (Hooker, et al., 2010). However, both [18F]SAHA and
[11C]MS-275 did not accumulate in the brain due to either excessive
washout, such as in the case of [18F]SAHA, or poor blood–brain barrier
(BBB) permeability, such as in the case of [11C]MS-275. As for the site
of radiolabeling, we elected not to label FAHA in sites other than in the
ﬂuoroacetyl moiety, because 6-amino-1-hexanoicanilide moiety pro-
duced as the result of HDAC-mediated cleavage of [18F]FAHA is lipophylic
and cannot be entrapped inside the cell, as it freely diffuses across the cell
membrane.
The results of our immunohistochemical (IHC) demonstrated a link
between the level of class IIa HDAC enzymes and the acetylation statusof certain lysine residues of several histone proteins in different struc-
tures of the brain, with the magnitude of [18F]FAHA accumulation in
the corresponding structures. In particular, high levels of [18F]FAHA ac-
cumulation observed in n. accumbens, and cerebellum were associated
with high expression levels of HDACs 4 and/or 5. These observations
are important, because HDACs 4 and 5 in n. accumbens are known to
play important roles in the development of drug addiction (Kumar et
al., 2005; Renthal et al., 2007). Consistent with previous reports (Broide
et al., 2007), in this study moderate levels of HDAC 5 expression and
hypoacetylation of H3 and H4were observed in the hippocampus, espe-
cially in CA2 and CA3 neurons, but lower levels in neurons of the dentate
gyrus. HDAC 5 expression in hippocampal neurons plays an important
role in the mechanism of depression (Tsankova et al., 2006). A stim-
ulation inducing long-term depression causes HDAC 5-mediated
deacetylation of H3 and H4 in the C/EBP gene promoter and prevents
the establishment of long-term potentiation (Guan et al., 2002).
Therefore, PET/CT/MRI with [18F]FAHA can expand the arsenal of
neuroimaging approaches and facilitate the longitudinal studies of
epigenetic mechanisms of addiction and depression.
Higher expression levels of HDACs 4, 5, and 9 observed in the cer-
ebellum explain higher levels of [18F]FAHA accumulation. Expression
of HDAC 4 in Purkinje cells is consistent with survival promoting
functions of HDAC 4 in Purkinje cells, which involves inhibition of
cyclin-dependent kinase-1 (CDK1) and prevents abortive cell-cycle
progression. In contrast, mice lacking HDAC 4 have elevated CDK1 ac-
tivity and display cerebellar abnormalities including a progressive
degeneration and loss of Purkinje neurons postnatally in posterior
lobes (Majdzadeh et al., 2008). Expression of HDAC 5 observed in cer-
ebellar granule cells is also consistent with its neuroprotective func-
tions (Bolger and Yao, 2005; Chawla et al., 2003; Linseman et al.,
2003). Noteworthy, is an almost complete deacetylation of lysine res-
idues of histone proteins (H2A-K5, H2B-K20, H3-K9, H3-K18, H3-K23,
and H4-K12) observed in Purkinje cells in the cerebellum, which war-
rants further studies to elucidate the signiﬁcance of these new ﬁndings.
In contrast to n. accumbens, hippocampus, and cerebellum, much lower
levels of class IIa HDAC expression and lower activity and a more pro-
nounced acetylation of histones were observed in the brain cortex and
white matter, which explains the lower accumulation of [18F]FAHA in
these tissues.
Pre-treatment of animals with increasing doses of HDAC inhibitor
SAHA (vorinostat) resulted in a dose-dependent decrease of the rate
constants k3FAHA and KiFAHA, in all structures of the brain, despite an in-
crease in [18F]FAHA blood input function (due to a decrease in systemic
catabolism of [18F]FAHA to [18F]FACE). Consistent with the results of
IHC studies, lower IC50 values for SAHA were determined for brain re-
gions expressing lower levels of class IIa HDACs (i.e., cortex), as com-
pared to higher IC50 values of SAHA for the brain structures expressing
class IIa HDACs at higher levels (i.e., n. accumbens, cerebellum).
Conclusions
Taken together, these results indicate that the unidirectional accu-
mulation of [18F]FAHA-derived radioactivity in the brain (KiFAHA) is
rate-limited by the level of expression-activity of HDAC class IIa en-
zymes in various structures of the brain, deﬁned in the current pharma-
cokinetic model by the rate constant k3FAHA. Therefore, PET imaging
with [18F]FAHA could beused as a pharmacodynamic biomarker of inhi-
bition of class IIa HDACs in the brain and facilitate the development and
clinical translation of novel class-IIa HDACIs.
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